Monte Rosa Therapeutics, Inc.
HealthcareNASDAQ:GLUE · NASDAQ Global Select
+$1.14 today
Vol 1.08M · Avg 1.01M
Intrinsic Value
GLUE Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Intrinsic Value
System DCF · consensus of 4 models
Sign in to unlock intrinsic value
Free accounts get 5 valuations per week. Upgrade for more.
Monitor GLUE
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price Alerts
Get notified when GLUE drops below a target
Sign in to activate price alerts · unlock IV-based targets
Valuation History
Is GLUE cheaper or more expensive than usual?
Review how the market has valued Monte Rosa Therapeutics, Inc. over time before deciding whether today’s discount or premium is unusual.
Price History
Dividend-adjusted closing price
Change
+271.38%
Period High
$25.31
Period Low
$4.19
Latest
$18.24
Analyst Targets
See where analysts expect GLUE to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street Price Targets
1-year price history with analyst consensus target
Current
$18.24
Low Target
$22.00
Avg Target
$31.75
High Target
$37.00
Upside (Avg)
+74.12%
Alternatives to GLUE
Compare Monte Rosa Therapeutics, Inc. with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Theravance Biopharma, Inc.
NASDAQ:TBPH
$857.84M
Geron Corporation
NASDAQ:GERN
$737.75M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Fundamental Analysis
Capture the investment case and test company quality
Write down the key idea, risks, and what would change your mind. Then review growth, profitability, returns, owner payouts, and insider activity.
My Notes
Journal entries for GLUE
Sign in to keep notes
Track your buy/sell/hold decisions for every stock in your personal journal.
Quality Snapshot
Start with the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | N/A |
Revenue | N/A | N/A | N/A | N/A |
Equity | N/A | N/A | -21.3% | -7.0% |
Cash | N/A | N/A | +45.4% | +133.3% |
ROIC | N/A | -30.6% | -32.3% | -13.6% |
Analysis
Latest growth is strongest in Cash at +133.3% and weakest in ROIC at -13.6%. Three-year average ROIC is -32.3%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$43.0M of revenue converted into -$130.0M of net income for the selected period. Gross margin is 88.0% and net margin is -745.3%, showing how much revenue survives after costs and taxes. EPS is $-1.86, tying the income statement back to per-share earnings.
Capital Efficiency
Measure how well Monte Rosa Therapeutics, Inc. turns capital into returns
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
-16.6%
avg -6.6%
ROIC
-13.6%
avg -56.9%
ROA
-8.6%
avg -38.1%
Analysis
ROA is currently the strongest return metric at -8.6% versus its period average of -38.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Owner Returns
Review how cash comes back to shareholders
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
0.00%
Buyback Yield (TTM)
0.00%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
0.00%
Analysis
Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Dividend Record
Check payout durability before counting on yield
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Company Overview
Understand how Monte Rosa Therapeutics, Inc. makes money
Finish by grounding the numbers in the company profile, leadership, balance sheet, and free cash flow.
Key Information
Leadership
Put the business in management context
Company facts explain what Monte Rosa Therapeutics, Inc. does; leadership context helps you judge who is responsible for capital allocation and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Markus Warmuth | President, Chief Executive Officer & Director | $1.08M | — | 55 | $594,538.00 | 0.91% |
Filip Janku | Chief Medical Officer | $833,600.00 | — | 52 | $65,837.00 | 0.10% |
Phil Nickson | Chief Business & Legal Officer | $833,600.00 | — | 47 | $55,000.00 | 0.08% |
Sharon Townson | Chief Scientific Officer | $644,600.00 | — | 51 | $73,845.00 | 0.11% |
John C. Castle | Chief Data & Information Officer | — | — | 55 | $78,500.00 | 0.12% |
Andrew Funderburk | Chief Investor Relations and Strategy Officer | — | — | — | $25,800.00 | 0.04% |
Magnus Walter DPHIL | Chief Technology Officer | — | — | — | — | — |
Matthew Bowen | Corporate Controller & Principal Accounting Officer | — | — | 37 | $19,500.00 | 0.03% |
Jennifer Champoux | Chief Operating Officer | — | — | 54 | $62,371.00 | 0.10% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
23
$2.06M
Net Sentiment
$2.06M
Net selling
Most Active
Warmuth Markus
9 transactions
1–10 of 23
Analysis
Insiders reported 0 buys worth $0.00 and 23 sells worth $2.06M over the last 12 months. That adds up to net selling of $2.06M. Warmuth Markus was the most active insider with 9 transactions.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $159.9M |
| Short-term Investments | $506.4M |
| Receivables | $4.6M |
| Other Current | $6.7M |
| Total Current Assets | $677.5M |
| PP&E (Net) | $53.1M |
| Other Non-current | $5.8M |
| Total Non-current Assets | $58.9M |
| Total Assets | $736.4M |
Analysis
Selected assets total $736.4M for Latest. The largest visible component is Short-term Investments at $506.4M, about 68.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Finish by testing whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Explore More
Continue the stock analysis
Jump to another research area for this company.